METTL3-dependent DLG2 Inhibits the Malignant Progression of Cervical Cancer by Inactivating the Hippo/YAP Signaling

Overview

Journal Hereditas

Date 2025 Jan 25

PMID 39856747

Authors

Mei Pu

Xia Xiao

Shasha Lv

Daqing Ran

Qian Huang

Mingming Zhou

Qirong Lei

Lingshuang Kong

Qing Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Discs large homolog 2 (DLG2) has been implicated in cancer development, yet its role in cervical cancer remains unclear. This study aims to explore the regulatory mechanism of DLG2 in cervical cancer and its clinical implications.

Methods: Quantitative reverse transcription polymerase chain reaction and western blotting assays were employed to detect RNA and protein expression, respectively. Colony formation assay, 5-Ethynyl-2'-deoxyuridine assay, flow cytometry, and transwell assays were conducted for cell functional analysis. A xenograft mouse model assay was performed to analyze tumor tumorigenesis in vivo. m6A RNA immunoprecipitation assay was used to analyze the association of METTL3 and DLG2.

Results: DLG2 was underexpressed in cervical cancer tissues and cells. Elevating DLG2 levels significantly suppressed cervical cancer cell proliferation, migration, and invasion, while promoting apoptosis. Additionally, DLG2 overexpression led to the deactivation of the Hippo/YAP signaling pathway. In vivo, DLG2 overexpression was shown to reduce tumor formation. We also discovered that METTL3 destabilized DLG2 mRNA through an m6A-dependent mechanism. Moreover, lowering DLG2 expression mitigated the effects of METTL3 silencing on cervical cancer cell malignancy.

Conclusion: DLG2 acted as a tumor suppressor in cervical cancer by inhibiting the Hippo/YAP signaling pathway. The METTL3-dependent regulation of DLG2 mRNA stability could be a critical factor in cervical cancer progression.

References

Li H, Wu X, Cheng X . Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016; 27(4):e43. PMC: 4864519. DOI: 10.3802/jgo.2016.27.e43. View

Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R . NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. J Natl Compr Canc Netw. 2023; 21(12):1224-1233. DOI: 10.6004/jnccn.2023.0062. View

Hu Y, Li Y, Huang Y, Jin Z, Wang C, Wang H . METTL3 regulates the malignancy of cervical cancer via post-transcriptional regulation of RAB2B. Eur J Pharmacol. 2020; 879:173134. DOI: 10.1016/j.ejphar.2020.173134. View

An Y, Duan H . The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022; 21(1):14. PMC: 8753874. DOI: 10.1186/s12943-022-01500-4. View

Kusakabe M, Taguchi A, Sone K, Mori M, Osuga Y . Carcinogenesis and management of human papillomavirus-associated cervical cancer. Int J Clin Oncol. 2023; 28(8):965-974. PMC: 10390372. DOI: 10.1007/s10147-023-02337-7. View

Moroishi T, Hansen C, Guan K . The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015; 15(2):73-79. PMC: 4562315. DOI: 10.1038/nrc3876. View

Cohen P, Jhingran A, Oaknin A, Denny L . Cervical cancer. Lancet. 2019; 393(10167):169-182. DOI: 10.1016/S0140-6736(18)32470-X. View

Wang Q, Guo X, Li L, Gao Z, Su X, Ji M . N-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 2020; 11(10):911. PMC: 7585578. DOI: 10.1038/s41419-020-03071-y. View

Li S, Yan G, Liu W, Li C, Wang X . Circ0106714 inhibits tumorigenesis of colorectal cancer by sponging miR-942-5p and releasing DLG2 via Hippo-YAP signaling. Mol Carcinog. 2020; 59(12):1323-1342. DOI: 10.1002/mc.23259. View

10.

Monk B, Colombo N, Tewari K, Dubot C, Caceres M, Hasegawa K . First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol. 2023; 41(36):5505-5511. DOI: 10.1200/JCO.23.00914. View

11.

Tewari K, Colombo N, Monk B, Dubot C, Caceres M, Hasegawa K . Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial. JAMA Oncol. 2023; 10(2):185-192. PMC: 10722390. DOI: 10.1001/jamaoncol.2023.5410. View

12.

Zeng C, Huang W, Li Y, Weng H . Roles of METTL3 in cancer: mechanisms and therapeutic targeting. J Hematol Oncol. 2020; 13(1):117. PMC: 7457244. DOI: 10.1186/s13045-020-00951-w. View

13.

Cunningham R, Hansen C . The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. Clin Sci (Lond). 2022; 136(3):197-222. PMC: 8819670. DOI: 10.1042/CS20201474. View

14.

Zhuang R, Bai X, Liu W . MicroRNA-23a depletion promotes apoptosis of ovarian cancer stem cell and inhibits cell migration by targeting DLG2. Cancer Biol Ther. 2019; 20(6):897-911. PMC: 6605979. DOI: 10.1080/15384047.2019.1579960. View

15.

Saito Y, Desai R, Muthuswamy S . Reinterpreting polarity and cancer: The changing landscape from tumor suppression to tumor promotion. Biochim Biophys Acta Rev Cancer. 2018; 1869(2):103-116. DOI: 10.1016/j.bbcan.2017.12.001. View

16.

Mutlu L, Tymon-Rosario J, Harold J, Menderes G . Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer. Expert Rev Anticancer Ther. 2022; 22(6):633-645. DOI: 10.1080/14737140.2022.2075348. View

17.

Keane S, de Weerd H, Ejeskar K . DLG2 impairs dsDNA break repair and maintains genome integrity in neuroblastoma. DNA Repair (Amst). 2022; 112:103302. DOI: 10.1016/j.dnarep.2022.103302. View

18.

Rahangdale L, Mungo C, OConnor S, Chibwesha C, Brewer N . Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022; 379:e070115. DOI: 10.1136/bmj-2022-070115. View

19.

Johnson R, Halder G . The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2013; 13(1):63-79. PMC: 4167640. DOI: 10.1038/nrd4161. View

20.

Keane S, Ameen S, Lindlof A, Ejeskar K . Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival. Cell Commun Signal. 2020; 18(1):65. PMC: 7171851. DOI: 10.1186/s12964-020-00553-6. View